Development of the vaccine, from Novavax, a Gaithersburg, Maryland-based company, was started at the same time as others in 2020, but the company struggled to produce its shot in large quantities.
Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine. It's late in the pandemic for a new choice, but Novavax is hoping to find a niche with those who are unvaccinated or need boosters. A federal vaccine advisory committee meets Tuesday to decide whether adult Americans could soon get a fourth COVID-19 vaccine option.
"There's a lot of reasons that are not scientifically based for not having taken the vaccine ," said Vivian Riefberg, a professor at the Darden School of Business at the University of Virginia."This may convince some people because it's traditional technology."which have been given to three-quarters of the American population
It's unclear how many people will want to get vaccinated with the two-dose Novavax shots, after declining the other three. The Novavax vaccine is already available in more than 40 countries and is expected to be particularly useful in low- and middle-income countries, which may not have the freezer capacity required for long-term storage of the mRNA vaccines. "We can't go and tell the rest of the world that we are not going to use it in our country but you should use it," he said.
It quickly proved safe and effective in lab and animal studies, though those took longer to complete than the mRNA research. If the plan had worked, he said, Novavax's shots would have been the best in the world. But the company's plan"had hiccups," Yadav said, including trouble attracting skilled people to staff all those facilities. The rollout was delayed in every country.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novavax hoping its COVID-19 vaccine using traditional technology wins over vaccine skepticsThe Novavax COVID-19 vaccine is made with an old school technology, but will it be enough to win over vaccine skeptics?
Baca lebih lajut »
FDA advisers meeting on Novavax, a latecomer in COVID-19 vaccine raceA federal advisory committee will vote on whether regulators should authorize a COVID-19 vaccine made by Novavax. From The New York Times.
Baca lebih lajut »
Novavax Covid-19 Vaccine Faces FDA Advisers’ ScrutinyThe outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern.
Baca lebih lajut »
FDA Advisers Consider Novavax COVID-19 Vaccine This WeekThe FDA’s vaccine advisors are scheduled to meet on Tuesday to consider authorizing the Novavax COVID-19 vaccine. The committee will vote on whether the benefits of the two-dose vaccine outweigh the risks for ages 18 and older.
Baca lebih lajut »
Why Variants Keep Covid-19 Cases Simmering in the U.S.A look at some of the Covid-19 data underlying Omicron’s recent spread suggests that an increasing share of Americans have some immunity against SARS-Cov-2, but the virus’s latest subvariant can sidestep our defenses.
Baca lebih lajut »
Orange County man to plead guilty to $5-million COVID-19 relief loan scamRaghavender Reddy Budamala reportedly used the loans to purchase a $1.2 million 'investment property' in Eagle Rock, a nearly $600,000 property in Malibu and a 'personal residence' in Irvine.
Baca lebih lajut »